Abecma denied for failing step therapy by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Apply Step-Therapy Requirements to Abecma

Step therapy — sometimes called "fail-first" — requires that a patient try one or more specified treatments before the insurer will cover the requested drug. For Abecma (idecabtagene vicleucel), a CAR-T therapy for relapsed or refractory multiple myeloma, step-therapy denials are unusual because the FDA-approved indication itself requires that patients have received prior lines of therapy. However, denials can still occur when Humana's internal policy requires a specific sequence or specific agents that the patient has not yet tried — or when documentation of prior therapies is incomplete and the reviewer cannot confirm the step requirements were met.

## Your Right to Appeal

Many states have enacted step-therapy reform laws giving patients the right to a step-therapy exception when a required step drug is contraindicated, has already been tried and failed, or would cause significant harm. Federal plans under ERISA are not bound by state step-therapy laws, but must still provide a full-and-fair review under ERISA §503 and access to independent external review under ACA §2719. External review must generally be requested within four months of the final internal denial. An expedited appeal (72 hours) is available when delay would seriously jeopardize health.

## Building Your Step-Therapy Exception Appeal

1. Map the step requirements — obtain Humana's published step-therapy criteria for Abecma or for CAR-T therapies in multiple myeloma. List each required prior therapy explicitly. 2. Document prior treatment history exhaustively — for each required step, provide chart documentation: drug name, start date, end date, best response documented in the medical record, and reason for discontinuation (progression on therapy, toxicity, or other clinical reason). Dates and outcomes are critical. 3. Address any gaps — if a required step drug was not tried because it was clinically inappropriate, the treating oncologist must document that clinical judgment in the chart and explain it in the medical-necessity letter. Reference the applicable NCCN guideline organization generically for support. 4. Prescriber letter — the hematologist/oncologist should write a letter that (a) lists every prior therapy with outcomes, (b) addresses each step criterion in Humana's policy, and (c) explains why any untried step drug is not appropriate given the patient's clinical profile. 5. Exception standard — if seeking a step-therapy exception, cite the applicable state law (if state-regulated plan) or request Humana's own exception criteria and address each one.

## Criteria-Mapping Structure

Create a two-column table: left column contains each required step verbatim from Humana's policy; right column cites the chart date, note, and documented outcome for that step. Attach treatment summaries and relevant progress notes as numbered exhibits.